The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | An insight into the MOMENTUM trial: safety and efficacy of momelotinib for the treatment of MF
In this video, Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the Phase III MOMENTUM trial (NCT04173494) comparing the use of momelotinib versus danazol in patients with myelofibrosis (MF) previously treated with a JAK inhibitor. Dr Verstovsek first provides some background information on the symptoms observed in these patients, including splenomegaly and anemia. Following this, Dr Verstovsek discusses the results of this study, as well as the safety and efficacy of momelotinib, and the potential approval of this agent in the US within the next year. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
